Clough Capital Partners L P Purchases Shares of 10,925 Kymera Therapeutics, Inc. $KYMR

Clough Capital Partners L P purchased a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 10,925 shares of the company’s stock, valued at approximately $850,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. US Bancorp DE increased its stake in Kymera Therapeutics by 9.8% in the third quarter. US Bancorp DE now owns 1,865 shares of the company’s stock valued at $106,000 after purchasing an additional 166 shares in the last quarter. Larson Financial Group LLC increased its stake in Kymera Therapeutics by 36.9% in the fourth quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock valued at $83,000 after purchasing an additional 287 shares in the last quarter. State Board of Administration of Florida Retirement System increased its stake in Kymera Therapeutics by 3.3% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 12,655 shares of the company’s stock valued at $985,000 after purchasing an additional 410 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after purchasing an additional 424 shares in the last quarter. Finally, Xponance LLC increased its stake in Kymera Therapeutics by 13.1% in the fourth quarter. Xponance LLC now owns 4,505 shares of the company’s stock valued at $351,000 after purchasing an additional 522 shares in the last quarter.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 30,000 shares of the firm’s stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $81.18, for a total transaction of $2,435,400.00. Following the transaction, the chief executive officer directly owned 666,195 shares in the company, valued at approximately $54,081,710.10. This trade represents a 4.31% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bruce Booth sold 5,900 shares of the firm’s stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $89.96, for a total value of $530,764.00. Following the transaction, the director owned 5,641 shares in the company, valued at approximately $507,464.36. This trade represents a 51.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 234,357 shares of company stock worth $19,072,496. 15.98% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $108.00 price target on shares of Kymera Therapeutics in a research note on Thursday, February 26th. Loop Capital set a $97.00 price target on shares of Kymera Therapeutics in a research note on Monday, June 8th. UBS Group lifted their price target on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the company a “buy” rating in a research note on Tuesday, March 3rd. Jefferies Financial Group assumed coverage on shares of Kymera Therapeutics in a research note on Monday, March 16th. They issued a “buy” rating and a $110.00 price target for the company. Finally, Stephens lifted their price target on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a research note on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $117.14.

Kymera Therapeutics Price Performance

NASDAQ:KYMR opened at $89.90 on Thursday. The firm has a 50-day moving average of $82.99 and a 200-day moving average of $80.75. The company has a market cap of $7.40 billion, a PE ratio of -25.18 and a beta of 2.02. Kymera Therapeutics, Inc. has a one year low of $36.65 and a one year high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.18. The company had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The firm’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.82) earnings per share. On average, equities research analysts expect that Kymera Therapeutics, Inc. will post -3.25 earnings per share for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.